SCHEMBL901463

SCHEMBL901463

N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.69
KDM4E B2RXH2 2/20 0.69
MEN1 O00255 2/20 0.69
TSHR P16473 2/20 0.69
KMT2A Q03164 2/20 0.69
LMNA P02545 1/20 0.69
MPO P05164 1/20 0.69
BLM P54132 1/20 0.69
PMP22 Q01453 1/20 0.69
HIF1A Q16665 1/20 0.69
KCNT1 Q5JUK3 1/20 0.61
EGFR P00533 2/20 0.59
SRC P12931 1/20 0.59
HDAC8 Q9BY41 1/20 0.56
BRS3 P32247 1/20 0.56
GAA P10253 1/20 0.56
HTT P42858 1/20 0.56
ALDH1A1 P00352 1/20 0.56
CYP3A4 P08684 1/20 0.56
ALOX15 P16050 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30736497 1.00 MAPT (0.69) MAPTKDM4EMEN1TSHRKMT2A
Hydrochloric Acid SCHEMBL9834221 0.99 MAPT (0.67) MAPTKDM4EMEN1TSHRKMT2A
Trifluoroacetic Acid SCHEMBL14762748 0.93 MAPT (0.60) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL8689585 0.90 HDAC8 (0.63) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL7613225 0.90 KMT2A (0.60) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL8689774 0.90 MAPT (0.63) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL8689768 0.90 MAPT (0.63) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL8398098 0.90 KDM4E (0.60) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL10691172 0.90 MAPT (0.60) MAPTKDM4EMEN1TSHRKMT2A
SCHEMBL8689596 0.90 HDAC8 (0.63) MAPTKDM4EMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160193359-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF SEATTLE GENETICS, INC. (US) 2016-07-07 US disclosed
US-20160193359-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF SEATTLE GENETICS, INC. (US) 2016-07-07 US disclosed
CN-103379912-B Positive carboxyalkyl ear statin and application thereof SEATTLE GENETICS, INC. (US) 2016-03-16 CN disclosed
US-20150246136-A1 NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME SEATTLE GENETICS, INC. (US) 2015-09-03 US disclosed
US-20150246136-A1 NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME SEATTLE GENETICS, INC. (US) 2015-09-03 US disclosed
EP-2621508-B1 N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF SEATTLE GENETICS INC (US) 2015-08-26 EP disclosed
US-20150148298-A1 N-CARBOXYALKYL-AURISTATIN AND USE THEREOF SEATTLE GENETICS, INC. (US) 2015-05-28 US disclosed
US-20150148298-A1 N-CARBOXYALKYL-AURISTATIN AND USE THEREOF SEATTLE GENETICS, INC. (US) 2015-05-28 US disclosed
US-20150148298-A1 N-CARBOXYALKYL-AURISTATIN AND USE THEREOF SEATTLE GENETICS, INC. (US) 2015-05-28 US disclosed
US-8992932-B2 Binder-drug conjugates (ADCs) and use thereof SEATTLE GENETICS, INC. (US) 2015-03-31 US disclosed
US-20130066055-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-14 US disclosed
WO-2012143496-A2 NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-10-26 WO disclosed
WO-2012143495-A2 NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-10-26 WO disclosed
WO-2012041805-A1 N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-05 WO disclosed
WO-2012041805-A1 N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-05 WO disclosed
US-7919468-B2 Compounds useful as modulators of the proteasome activity CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2011-04-05 US disclosed
US-7919468-B2 Compounds useful as modulators of the proteasome activity CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2011-04-05 US disclosed
US-20090069222-A1 Compounds Useful as Modulators of the Proteasome Activity CENTRE NATIONAL DE AL RECHERCHE SCIENTIFIQUE (FR) 2009-03-12 US disclosed
US-20090069222-A1 Compounds Useful as Modulators of the Proteasome Activity CENTRE NATIONAL DE AL RECHERCHE SCIENTIFIQUE (FR) 2009-03-12 US disclosed
WO-2006105811-A1 COMPOUNDS USEFUL AS MODULATORS OF THE PROTEASOME ACTIVITY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130066055-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF CDK4, CDKL4, FLT4 MAPT 2019/4885KDM4E 827/4885MEN1 843/4885
US-20160193359-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF CDK4, CDKL4, FLT4 MAPT 2019/4885KDM4E 827/4885MEN1 843/4885
US-20090069222-A1 Compounds Useful as Modulators of the Proteasome Activity PSMB10, PSMB11, PSMB6 MAPT 3169/4885KDM4E 2618/4885MEN1 2013/4885
US-20150148298-A1 N-CARBOXYALKYL-AURISTATIN AND USE THEREOF HDGF, HGFAC, HGF MAPT 2920/4885KDM4E 2155/4885MEN1 732/4885
US-20150246136-A1 NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME DDR1, IGFBP6, KDR MAPT 921/4885KDM4E 2107/4885MEN1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.